[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies
- Autores
- Audicio, Paola F.; Castellano, Gustavo Eugenio; Tassano, Marcos R.; Rezzano, Maria E.; Fernandez, Marcelo; Riva, Eloisa; Robles, Ana; Cabral, Pablo; Balter, Henia; Oliver, Patricia
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin’s Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. MonteCarlo simulation showed high doses deposited on a spheroid tumor mass model. This method shows to be an appropiate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.
Fil: Audicio, Paola F.. Universidad de la República; Uruguay
Fil: Castellano, Gustavo Eugenio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Física Enrique Gaviola. Universidad Nacional de Córdoba. Instituto de Física Enrique Gaviola; Argentina
Fil: Tassano, Marcos R.. Universidad de la República; Uruguay
Fil: Rezzano, Maria E.. Universidad de la República; Uruguay
Fil: Fernandez, Marcelo. Universidad de la República; Uruguay
Fil: Riva, Eloisa. Hospital de Clínicas; Uruguay
Fil: Robles, Ana. Universidad de la República; Uruguay
Fil: Cabral, Pablo. Universidad de la República; Uruguay
Fil: Balter, Henia. Universidad de la República; Uruguay
Fil: Oliver, Patricia. Universidad de la República; Uruguay - Materia
-
CD20
Non-Hodgkin Lymphoma
177Lu
Radioimmunotherapy - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/271298
Ver los metadatos del registro completo
| id |
CONICETDig_e58d859539d9e90cc52cded4977c2b39 |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/271298 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studiesAudicio, Paola F.Castellano, Gustavo EugenioTassano, Marcos R.Rezzano, Maria E.Fernandez, MarceloRiva, EloisaRobles, AnaCabral, PabloBalter, HeniaOliver, PatriciaCD20Non-Hodgkin Lymphoma177LuRadioimmunotherapyhttps://purl.org/becyt/ford/1.3https://purl.org/becyt/ford/1Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin’s Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. MonteCarlo simulation showed high doses deposited on a spheroid tumor mass model. This method shows to be an appropiate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.Fil: Audicio, Paola F.. Universidad de la República; UruguayFil: Castellano, Gustavo Eugenio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Física Enrique Gaviola. Universidad Nacional de Córdoba. Instituto de Física Enrique Gaviola; ArgentinaFil: Tassano, Marcos R.. Universidad de la República; UruguayFil: Rezzano, Maria E.. Universidad de la República; UruguayFil: Fernandez, Marcelo. Universidad de la República; UruguayFil: Riva, Eloisa. Hospital de Clínicas; UruguayFil: Robles, Ana. Universidad de la República; UruguayFil: Cabral, Pablo. Universidad de la República; UruguayFil: Balter, Henia. Universidad de la República; UruguayFil: Oliver, Patricia. Universidad de la República; UruguayPergamon-Elsevier Science Ltd2011-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/271298Audicio, Paola F.; Castellano, Gustavo Eugenio; Tassano, Marcos R.; Rezzano, Maria E.; Fernandez, Marcelo; et al.; [177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies; Pergamon-Elsevier Science Ltd; Applied Radiation and Isotopes; 69; 7; 7-2011; 924-9280969-8043CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S0969804311000406info:eu-repo/semantics/altIdentifier/doi/10.1016/j.apradiso.2011.01.026info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:52:42Zoai:ri.conicet.gov.ar:11336/271298instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:52:42.981CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies |
| title |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies |
| spellingShingle |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies Audicio, Paola F. CD20 Non-Hodgkin Lymphoma 177Lu Radioimmunotherapy |
| title_short |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies |
| title_full |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies |
| title_fullStr |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies |
| title_full_unstemmed |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies |
| title_sort |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies |
| dc.creator.none.fl_str_mv |
Audicio, Paola F. Castellano, Gustavo Eugenio Tassano, Marcos R. Rezzano, Maria E. Fernandez, Marcelo Riva, Eloisa Robles, Ana Cabral, Pablo Balter, Henia Oliver, Patricia |
| author |
Audicio, Paola F. |
| author_facet |
Audicio, Paola F. Castellano, Gustavo Eugenio Tassano, Marcos R. Rezzano, Maria E. Fernandez, Marcelo Riva, Eloisa Robles, Ana Cabral, Pablo Balter, Henia Oliver, Patricia |
| author_role |
author |
| author2 |
Castellano, Gustavo Eugenio Tassano, Marcos R. Rezzano, Maria E. Fernandez, Marcelo Riva, Eloisa Robles, Ana Cabral, Pablo Balter, Henia Oliver, Patricia |
| author2_role |
author author author author author author author author author |
| dc.subject.none.fl_str_mv |
CD20 Non-Hodgkin Lymphoma 177Lu Radioimmunotherapy |
| topic |
CD20 Non-Hodgkin Lymphoma 177Lu Radioimmunotherapy |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.3 https://purl.org/becyt/ford/1 |
| dc.description.none.fl_txt_mv |
Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin’s Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. MonteCarlo simulation showed high doses deposited on a spheroid tumor mass model. This method shows to be an appropiate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical. Fil: Audicio, Paola F.. Universidad de la República; Uruguay Fil: Castellano, Gustavo Eugenio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Física Enrique Gaviola. Universidad Nacional de Córdoba. Instituto de Física Enrique Gaviola; Argentina Fil: Tassano, Marcos R.. Universidad de la República; Uruguay Fil: Rezzano, Maria E.. Universidad de la República; Uruguay Fil: Fernandez, Marcelo. Universidad de la República; Uruguay Fil: Riva, Eloisa. Hospital de Clínicas; Uruguay Fil: Robles, Ana. Universidad de la República; Uruguay Fil: Cabral, Pablo. Universidad de la República; Uruguay Fil: Balter, Henia. Universidad de la República; Uruguay Fil: Oliver, Patricia. Universidad de la República; Uruguay |
| description |
Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin’s Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. MonteCarlo simulation showed high doses deposited on a spheroid tumor mass model. This method shows to be an appropiate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical. |
| publishDate |
2011 |
| dc.date.none.fl_str_mv |
2011-07 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/271298 Audicio, Paola F.; Castellano, Gustavo Eugenio; Tassano, Marcos R.; Rezzano, Maria E.; Fernandez, Marcelo; et al.; [177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies; Pergamon-Elsevier Science Ltd; Applied Radiation and Isotopes; 69; 7; 7-2011; 924-928 0969-8043 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/271298 |
| identifier_str_mv |
Audicio, Paola F.; Castellano, Gustavo Eugenio; Tassano, Marcos R.; Rezzano, Maria E.; Fernandez, Marcelo; et al.; [177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies; Pergamon-Elsevier Science Ltd; Applied Radiation and Isotopes; 69; 7; 7-2011; 924-928 0969-8043 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S0969804311000406 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.apradiso.2011.01.026 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Pergamon-Elsevier Science Ltd |
| publisher.none.fl_str_mv |
Pergamon-Elsevier Science Ltd |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1846782220405047296 |
| score |
12.982451 |